We plan to expand our existing capabilities in biologics to enable access to a wider range of molecules for studying diverse proteins and drug targets with the optimal chemical tools.
Specifically, this new platform will position the IBRI to:
- Pursue strategic drug discovery opportunities within and external to the IBRI that represent compelling opportunities to impact underserved diseases.
- Address limitations of emerging molecular therapeutic modalities to improve scope and effectiveness in targeting disease.
- Integrate molecular capabilities into innovative discovery platforms to expand therapeutic possibilities and value creation.